Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TILDRAKIZUMAB Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of SUNPG1623

NCT02980692
View directory record Official record
Conditions
Active Psoriatic Arthritis
Interventions
SUNPG1623 I, SUNPG1623 II, SUNPG1623 III, SUNPG1623 IV, PLACEBO
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Sep 30, 2026, 5:45 PM EDT
Active, not recruiting Phase 3 Interventional

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

NCT04991116
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
TILD sub-cutaneous (SC) injection
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
41
States / cities
Dothan, Alabama • Gilbert, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

NCT04314544
View directory record Official record
Conditions
Active Psoriatic Arthritis
Interventions
TILD, matching placebo injections
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
45
States / cities
Dothan, Alabama • Gilbert, Arizona • Glendale, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

NCT03997786
View directory record Official record
Conditions
Moderate-to-severe Chronic Plaque Psoriasis
Interventions
Tildrakizumab, Placebo, Etanercept
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
6 Years to 215 Months
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
5
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Tildrakizumab on Epigenetic Age

NCT05110313
View directory record Official record
Conditions
Psoriasis, Aging, Epigenetic Disorder, Inflammation; Skin
Interventions
TILDRAKIZUMAB
Biological
Lead sponsor
Carlos Wambier
Other
Eligibility
35 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 30, 2026, 5:45 PM EDT
Recruiting Not applicable Interventional

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

NCT06399432
View directory record Official record
Conditions
Psoriasis
Interventions
Mediterranean Diet
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 94 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

NCT03897088
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
PART 1: Double-blind Placebo-controlled, PART 2: Double-blind Active Treatment Extension
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Encinitas, California • Fountain Valley, California • Fremont, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 30, 2026, 5:45 PM EDT
Recruiting Phase 4 Interventional

Psoriatic Immune Response to Tildrakizumab

NCT05390515
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Tildrakizumab Prefilled Syringe
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

NCT03897075
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Interventions
Tildrakizumab, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Encinitas, California • Fountain Valley, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

NCT04112810
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Tildrakizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 30, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

NCT04541329
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Tildrakizumab
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 30, 2026, 5:45 PM EDT
Recruiting No phase listed Observational

Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

NCT03992729
View directory record Official record
Conditions
Pregnancy Related
Interventions
Pregnant women exposed to tildrakizumab, Pregnant women not exposed to tildrakizumab
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

NCT03552276
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
SUNPG18_07 I (Tildrakizumab 200 mg), SUNPG18_07 II (Tildrakizumab 100 mg)
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
13
States / cities
Glendale, Arizona • Phoenix, Arizona • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 30, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

NCT03718299
View directory record Official record
Conditions
Psoriasis
Interventions
Injections of tildrakizumab
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
San Diego, California • Grandville, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 30, 2026, 5:45 PM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Recruiting Phase 4 Interventional

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

NCT04347473
View directory record Official record
Conditions
Psoriasis
Interventions
Ilumya Injectable Product
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Sep 30, 2026, 5:45 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

NCT06611163
View directory record Official record
Conditions
Moderate to Severe Genital Psoriasis
Interventions
Tildrakizumab 100 mg, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Anaheim, California • Encinitas, California • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

NCT04314531
View directory record Official record
Conditions
Active Psoriatic Arthritis
Interventions
TILD, matching placebo injections
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Covina, California • Miami Beach, Florida • New Port Richey, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 30, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

MIcrovascular dysfuNction In Moderate-severe Psoriasis

NCT04271540
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Tildrakizumab
Drug
Lead sponsor
Marcelo F. Di Carli, MD, FACC
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 30, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of SUNPG1622

NCT02980705
View directory record Official record
Conditions
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Interventions
SUNPG1622 I dose, Placebo dose
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 30, 2026, 5:45 PM EDT